About DynavaxDynavax Technologies Corporation discovers.

For more information, please visit.. About DynavaxDynavax Technologies Corporation discovers, develops and innovative innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory diseases using versatile, proprietary approaches, the immune responses change in highly specific ways. Our TLR9 agonist on immunostimulatory sequences or ISS, the short DNA sequences Ourrol is improving the ability of the immune system to fight diseases and chronic inflammation. Our product candidates are: HEPLISAV, a hepatitis B vaccine in Phase 3; TOLAMBA , a ragweed allergy immunotherapy, a treatment for non-Hodgkin’s lymphoma in Phase 2 and for metastatic colorectal cancer in Phase 1 and a therapy for hepatitis B also in Phase 1 Our preclinical asthma and COPD program is partnered with AstraZeneca.

The patient enrollment in the multicenter phase 3 registration study known as PHAST started in Germany on 14 This comparative immunogenicity study, initiated in late 2006 in Canada, enrolling subjects 55 years old 55 years old. A two – dose HEPLISAV administered at 0 and 1 month to the conventional three doses of Engerix-B by GlaxoSmithKline marketed. The total enrollment target for the Phase 3 registration trial in Canada and in Germany approximately 2,000 subjects.Applies to to 80 percent of young people as well as few adults, acne does not only cause clinical problems as well as grave social, psychological and emotional problems. Prominent result of the bacterium Propionibacterium acnes at a strong increase of settlement density at puberty, some research proposes, acnes may only responsible for the inflammatory rather than the real cause of to the infections.

P. Claim acne Yet – Yet – uncultivated germs.

A recent study, researchers of the University of Aarhus, Danish find bacteria into the follicle of acne patients and healthy individuals with those of the known species to be, dispute the theory that acne is caused by some of for to bacteria. They report their findings in the October 2008 issue the Journal of Clinical Microbiology.